🔔 Pope McGlamry and the Zantac Recall Litigation

Zantac (Ranitidine) Litigation and Recall

Mike McGlamry was appointed by the Honorable Robin L. Rosenberg to the Initial Census Team in the Zantac (Ranitidine) Products Liability Litigation in the United States District Court for the Southern District of Florida. The Initial Census Team was formed to create an early census process that requires claimants to show that they were exposed to and injured by Zantac by submitting proof of their cancer diagnosis and proof that they used Zantac/ranitidine products. On April 3, 2020, Mike was also appointed by the Court to be responsible for all filings and submissions on behalf of the plaintiffs, and is further responsible for directing all work related to discovery during the COVID-19 crisis. We are proud to be a part of this team and look forward to helping those harmed by Zantac/Ranitidine usage.

Mike McGlamry. 404-523-7706. mmcglamry@pmkm.com

Zantac/ranitidine is an antacid and antihistamine that was commonly used to treat and prevent heartburn, and treat stomach ulcers, gastroesophageal reflux disease (GERD), and conditions that cause too much stomach acid. On April 1, 2020, the Food and Drug Administration (FDA) requested that all manufacturers immediately withdraw prescription and over-the-counter (OTC) Zantac/ranitidine products due to excess levels of NDMA, a probable human carcinogen in the drug that has also been found in rocket fuel. The FDA noted that its ongoing investigation of Zantac/ranitidine has determined that levels of NDMA increase over time and when stored at higher-than-normal temperatures. Consumers have been advised to stop taking any Zantac/ranitidine tablets or liquid medications.

Pope McGlamry is investigating cases on behalf of individuals who took over-the-counter or prescription Zantac/ranitidine for at least one year and were thereafter diagnosed with cancer. Please contact us if you would like more information or would like to associate on any cases with us.

Visit Our Website For More Information

Kirk Pope 404-523-7706
kirkpope@pmkm.com

Courtney Mohammadi 404-523-7706

courtneymohammadi@pmkm.com

Caroline McGlamry 404-523-7706

carolinemcglamry@pmkm.com

Zantac in the News

The US Food and Drug Administration has request ed that manufacturers pull all prescription and over-the-counter ranitidine drugs, known by the brand name Zantac, from the market immediately. Keep Reading on CNN.